Hims & Hers Health Stock Gains On Solid Q1, FY22 Outlook

  • Hims & Hers Health Inc HIMS reported fourth-quarter FY21 sales growth of 104% year-on-year, to $84.7 million, beating the consensus of $76.79 million.
  • The average order value for the quarter was $74. Q4 2021 ending member subscriptions grew 95% year-over-year to 609,000.
  • The gross profit margin contracted 400 basis points Y/Y to 73%, and the gross profit rose 94.7% Y/Y to $62.1 million.
  • The loss from operations widened to $(21.6) million.
  • The company held $247 million in cash and equivalents as of December 31, 2021.
  • EPS of $(0.15) missed the analyst consensus of $(0.07).
  • The adjusted EBITDA loss widened to $(7.1) million.
  • Outlook: Hims & Hers sees Q1 sales of $90 million - $93 million versus the consensus of $77.92 million.
  • The company expects FY22 sales of $365 million - $380 million against the consensus of $350.75 million.
  • Price Action: HIMS shares are trading higher by 14.5% at $4.78 in premarket on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!